Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
02:12pm, Tuesday, 11'th Feb 2020
The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
02:12pm, Tuesday, 11'th Feb 2020
The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.
3 Top Biotech Stocks to Buy in February
01:29pm, Sunday, 09'th Feb 2020
These three clinical-stage biotechs could all double in value before year's end.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
02:21pm, Wednesday, 05'th Feb 2020
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
02:21pm, Wednesday, 05'th Feb 2020
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
Zacks: Brokerages Anticipate Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Will Announce Earnings of -$0.57 Per Share
10:42am, Wednesday, 22'nd Jan 2020
Equities analysts expect that Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) will announce earnings per share of ($0.57) for the current quarter, Zacks reports. Zero analysts have issued estimates for Kini
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Lowered to Buy at ValuEngine
11:48am, Sunday, 19'th Jan 2020
ValuEngine lowered shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday, ValuEngine reports. Several other resea
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Lowered to "Sell" at Zacks Investment Research
06:56am, Saturday, 18'th Jan 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday, Zacks.com reports. According to
Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
01:00pm, Monday, 13'th Jan 2020
- Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 -- Enrollment target achieved for mavrilimumab Phase 2.
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
03:13pm, Thursday, 19'th Dec 2019
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
07:27pm, Wednesday, 18'th Dec 2019
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
Did Hedge Funds Drop The Ball On Kiniksa Pharmaceuticals, Ltd. (KNSA) ?
12:29pm, Monday, 16'th Dec 2019
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy
02:59pm, Thursday, 12'th Dec 2019
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector
02:47pm, Wednesday, 11'th Dec 2019
Biotechs represent some of the most difficult to gauge investment opportunities on the Street. This is because shares can make big moves in either direction given a single catalyst, making these stock
Kite will be the sponsor of this study and will be responsible for its conduct. “We were excited to present data from several abstracts at the recent ASH meeting that build upon our understanding o
